Androgen biosynthesis (CYP17) inhibitor
Abiraterone acetate
Brand names: Zytiga
Adult dose
Dose: 1000 mg with prednisolone 5–10 mg
Route: Oral
Frequency: Once daily on empty stomach
Clinical pearls
- For metastatic prostate cancer with steroid cover
- Take ≥1 h before or 2 h after food (food increases exposure)
Contraindications
- Severe hepatic impairment
Side effects
- Hypertension
- Hypokalaemia
- Fluid retention
- Hepatotoxicity
Interactions
- CYP3A4 inducers (avoid)
- CYP2D6 substrates (e.g. metoprolol)
Monitoring
- BP, K+, LFTs
- PSA
Reference: BNF; NICE TA387/TA721; EAU; SmPC Zytiga. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Acute Myeloid Leukaemia Presentation · BSH; NICE — NG146
- Tumour Lysis Syndrome · Cairo-Bishop; BSH; NICE — Best Practice
- Renal Colic — ED Workflow · NICE NG118 (2019); BAUS 2018
- Acute Scrotum · BAUS 2018; EAU 2024
- Continence Assessment · NICE NG123 (2019)
- Recurrent UTI in Women · NICE NG112 / CKS; EAU 2024